FOLH1 and posterior cortical atrophy: In particular, prostate-specific membrane antigen (PSMA) ligand PET imaging has revolutionized the diagnostic management of PCa patients, enabling the detection of a large number of metastases undetectable with conventional imaging modalities, even in atypical sites [9,10] (Figure 1).